Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Di Leo

Showing results (71-80 of 187) with videos related to

Pageof 19
Sort By:
NPJ Breast Cancer|September 5, 2019
Metabolomic analysis of serum may refine 21-gene expression assay risk recurrence stratificationAmelia McCartney, Alessia Vignoli, Leonardo Tenori, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2013
Adjuvant chemotherapy: which patient? What regimen?Natalie Turner, Laura Biganzoli, Luca Malorni, et al.
Breast (Edinburgh, Scotland)|April 5, 2015
New approaches for improving outcomes in breast cancer in EuropeAngelo Di Leo, Giuseppe Curigliano, Véronique Diéras, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2009
Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancerRichard S Finn, Michael F Press, Judy Dering, et al.
Cancers|June 2, 2021
Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast CancerIlenia Migliaccio, Angela Leo, Francesca Galardi, et al.
Molecular Oncology|December 26, 2014
Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patientsMarta Pestrin, Francesca Salvianti, Francesca Galardi, et al.
Breast Cancer (Tokyo, Japan)|May 13, 2019
A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancerJohn F R Robertson, Zefei Jiang, Angelo Di Leo, et al.
International Journal of Radiation Oncology, Biology, Physics|September 8, 2018
In Reply to Belkacemi and TsoutsouYoussef H Zeidan, Joyce G Habib, Evandro de Azambuja, et al.
Anticancer Research|August 1, 2018
Platinum-based Agent and Fluorouracil in Metastatic Breast Cancer: A Retrospective Monocentric Study with a Review of the LiteratureLorenzo Rossi, Chiara Biagioni, Amelia McCartney, et al.
Breast (Edinburgh, Scotland)|April 29, 2014
Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapyIvana Bozovic-Spasojevic, Lieveke Ameye, Marianne Paesmans, et al.
Pageof 19

Showing results (71-80 of 187) with videos related to

Sort By:
Pageof 19
NPJ Breast Cancer|September 5, 2019
Metabolomic analysis of serum may refine 21-gene expression assay risk recurrence stratificationAmelia McCartney, Alessia Vignoli, Leonardo Tenori, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2013
Adjuvant chemotherapy: which patient? What regimen?Natalie Turner, Laura Biganzoli, Luca Malorni, et al.
Breast (Edinburgh, Scotland)|April 5, 2015
New approaches for improving outcomes in breast cancer in EuropeAngelo Di Leo, Giuseppe Curigliano, Véronique Diéras, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2009
Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancerRichard S Finn, Michael F Press, Judy Dering, et al.
Cancers|June 2, 2021
Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast CancerIlenia Migliaccio, Angela Leo, Francesca Galardi, et al.
Molecular Oncology|December 26, 2014
Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patientsMarta Pestrin, Francesca Salvianti, Francesca Galardi, et al.
Breast Cancer (Tokyo, Japan)|May 13, 2019
A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancerJohn F R Robertson, Zefei Jiang, Angelo Di Leo, et al.
International Journal of Radiation Oncology, Biology, Physics|September 8, 2018
In Reply to Belkacemi and TsoutsouYoussef H Zeidan, Joyce G Habib, Evandro de Azambuja, et al.
Anticancer Research|August 1, 2018
Platinum-based Agent and Fluorouracil in Metastatic Breast Cancer: A Retrospective Monocentric Study with a Review of the LiteratureLorenzo Rossi, Chiara Biagioni, Amelia McCartney, et al.
Breast (Edinburgh, Scotland)|April 29, 2014
Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapyIvana Bozovic-Spasojevic, Lieveke Ameye, Marianne Paesmans, et al.
Pageof 19